AstraZeneca (AZN) said its Trixeo Aerosphere, a treatment for chronic obstructive pulmonary disease in adults, received a positive opinion from a committee of the European Medicines Agency for use with a "next-generation" pressurized inhaler propellant that has near-zero global warming potential.
The positive opinion from the Committee for Medicinal Products for Human Use was based on results from a clinical program showing bioequivalence between the new propellant and the current propellant, AstraZeneca said Friday in a statement.
Trixeo is the first medicine delivered via inhaler using a propellant designed to minimize environmental impact, the company said.
The transition in the EU to the new propellant will begin in the coming months, the company said.
AstraZeneca shares fell 1.5% in recent Friday trading.
Price: 72.57, Change: -1.11, Percent Change: -1.51
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。